



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Case No. 05-082)**

**In re Application of:**

**Ursula Giesen, et al.**

**Serial No.: 10/525,883**

**Filed: February 24, 2005**

**For: Generation of Chemiluminescence by  
Hydrogen**

)  
)  
)  
)  
)  
)  
)  
)  
)  
)  
)

**Group Art Unit: To be assigned**

**Examiner: To be assigned**

**SUPPLEMENTAL**  
**INFORMATION DISCLOSURE STATEMENT**

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

McDonnell, Boehnen, Hulbert & Berghoff LLP  
300 S. Wacker Drive, Suite 3100  
Chicago, IL 60606  
312-913-0001

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. §1.97 (b)
- ☐ **after** three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):
- ☐ the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below)

**OR**

- ☐ the fee of \$180.00 set forth in 37 C.F.R. § 1.17(p) (see "Fees" below).
- ☐ **after** a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see "Fees" and "Method of Payment of Fees" below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

#### CERTIFICATION

- ☐ The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

- ☒ No fee is owed by the applicant(s).  
☐ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.  
☐ The **Petition Fee of \$130.00** set forth in 37 C.F.R. § 1.17(i) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☐ Attached is a check in the amount of \$180.00.  
☐ Charge Deposit Account No. 13-2490 in the amount of \$ . (A duplicate copy of this communication is enclosed for that purpose.)

Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490. A duplicate copy of this communication is enclosed for this purpose.

**CERTIFICATE OF MAILING AS "EXPRESS MAIL" (37 CFR 1.10)** I hereby certify that this correspondence and all attached paper(s) or fee(s) is being deposited with sufficient postage, with the United States Postal Service as EXPRESS MAIL POST OFFICE TO ADDRESSEE in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, with sufficient postage, on this 17<sup>th</sup> Day of October, 2005. under Express Mail Certificate No. EV723821119US.

Date: 10/17/05

Respectfully submitted,



David S. Harper  
Registration No. 42,636

Telephone: 312-913-0001  
Facsimile: 312-913-0002

**McDonnell Boehnen Hulbert & Berghoff LLP**  
300 South Wacker Drive  
Chicago, IL 60606

McDonnell, Boehnen, Hulbert & Berghoff LLP  
300 S. Wacker Drive, Suite 3100  
Chicago, IL 60606  
312-913-0001

### **U.S. Patent Documents**

1. Müller, et al., U.S. Patent No. 4,745,076, Issued on May 17, 1988.
2. Hans-Peter Josel, et al. U.S. Patent No. 5,958,783, Issued on September 28, 1999.
3. Rupert Herrmann, et al., U.S. Patent No. 5,981,286, Issued November 9, 1999.

### **Foreign Documents**

4. Francis Müller, et al., European Patent Application No. 0 178 450, Issued on April 23, 1986.
5. Kotzan, Holger, Dr., et al., (English Translation) of European Patent No. EP A 0 658 760, Issued June 21, 1995.

### **Article References**


6. Blackburn, et al., (1991), Clinical Chemistry, "Electrochemiluminescence Detection for Development of Immunoassays and DNA Probe Assays for Clinical Diagnostics", Vol: 37(9), pp. 1534-1539.
7. Misik, et al., Annals New York Academy of Sciences "Free Radical Intermediates in Sonodynamic Therapy", pp. 335-348.
8. Leland, et al., (1990), J. Electrochem. Soc., "Electrogenerated Chemiluminescence: An Oxidative-Reduction Type ECL Reaction Sequence Using Tripropyl Amine", Vol: 137 (10), pp. 3127-3131.
9. Suslick, et al., (1999), Annu. Rev. Mater. Sci., "Application of Ultrasound to Materials Chemistry", Vol: 29, pp. 295-326.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider

it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully Submitted,

Date: 10/17/05

By:   
David S. Harper  
Reg. No. 42,636

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

05-082

Serial No.

10/525,883



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

Franz Wieckmann, et al.

**Filing Date:**

February 24, 2005

**Group:**

To be assigned

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	4,745,076	May 17, 1988	Francis Müller			September 9, 1985
	2.	5,958,783	September 28, 1999	Hans-Peter Josel			July 24, 1995
	3.	5,981,286	November 9, 1999	Rupert Herrmann			July 24, 1995

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	4.	0 178 450	April 23, 1986	Europe				X
	5.	EP A 0 658 760	June 21, 1995	Europe			X	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

	6.	Blackburn, et al., (1991), Clinical Chemistry, "Electrochemiluminescence Detection for Development of Immunoassays and DNA Probe Assays for Clinical Diagnostics", Vol: 37(9), pp. 1534-1539.
	7.	Misik, et al., Annals New York Academy of Sciences "Free Radical Intermediates in Sonodynamic Therapy", pp. 335-348.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

05-082

Serial No.

10/525,883



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

Franz Wieckmann, et al.

**Filing Date:**

February 24, 2005

**Group:**

To be assigned

8.	Leland, et al., (1990, J. Electrochem. Soc., "Electrogenerated Chemiluminescence: An Oxidative-Reduction Type ECL Reaction Sequence Using Tripropyl Amine", Vol: 137(10), pp. 3127-3131.
9.	Suslick, et al., (1999), Annu. Rev. Mater. Sci., "Application of Ultrasound to Materials Chemistry", Vol: 29, pp. 295-326.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.